Understanding the Functional Dependence and Inhibition of the Bcl‑2 Pro-Survival Proteins in a Wide Spectrum of...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Precision cancer medicine aims to enhance treatment efficacy through targeted therapies.
• Bcl-2 pro-survival proteins are key targets in cancer, with Venetoclax as a notable inhibitor.
• Functional assays can refine the application of targeted therapies in clinical settings.

Purpose of the Study:

• To evaluate BH3 profiling as a functional diagnostic tool for identifying antiapoptotic Bcl-2 family protein dependencies across diverse human cancers.
• To assess the sensitivity of various cancer types to BH3 mimetics, including Bcl-2, Mcl-1, and Bcl-xL inhibitors.
• To explore novel therapeutic strategies for precision cancer medicine based on functional protein dependencies.

Main Methods:

• BH3 profiling was performed on hematological and solid tumor cell lines, including ovarian cancer patient-derived xenograft (PDX) models.
• Sensitivity to selective Bcl-2 family inhibitors (Venetoclax, Mcl-1 inhibitors, Bcl-xL inhibitors) was assessed.
• Immunohistochemistry was used to analyze protein expression in patient-derived lymphoma samples.

Main Results:

• Hematological cancer cell lines generally showed sensitivity to Bcl-2 or Mcl-1 inhibitors.
• Specific lymphoma subtypes exhibited distinct dependencies on Bcl-2 (B-cell) or Mcl-1 (T-cell).
• Most solid tumors required combined Bcl-xL and Mcl-1 inhibition for significant apoptosis induction, and Bfl-1 was implicated in T-cell lymphomas.

Conclusions:

• BH3 profiling effectively identifies functional dependencies on antiapoptotic Bcl-2 family proteins in various cancers.
• Hematological malignancies display specific vulnerabilities to Bcl-2 or Mcl-1 inhibition.
• Combined inhibition of Bcl-xL and Mcl-1 shows promise for treating solid tumors, and Bfl-1 presents a potential therapeutic target in T-cell lymphomas.